Merck has opened a new €25 million BioReliance testing facility at its global headquarters in Darmstadt, Germany, expanding critical testing capabilities for biopharmaceutical companies developing and commercializing next-generation therapies across Europe.

 

The new 2,000-square-meter facility will provide commercial drug substance and drug product release testing, along with stability testing services, helping customers meet increasingly complex quality and regulatory requirements closer to their markets.

 

"As demand for biologics and novel therapies continues to grow, our customers need reliable, compliant testing capabilities closer to where their products are developed and commercialized,” said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck. 

 

“Our new testing facility combines best-in-class analytical characterization services with more than 75 years of BioReliance® expertise to help our European customers move critical therapies toward patients with greater speed and confidence.”

 

The facility strengthens Merck’s ability to support biopharmaceutical companies from early development through commercial launch. It will provide Good Manufacturing Practice (GMP)-compliant stability studies for monoclonal antibodies and cell therapies, addressing rising demand for advanced biologics testing across Europe.

 

Merck expects the site’s workforce to grow significantly over the coming years as customer demand increases, creating new opportunities to expand its regional testing capabilities.

 

Strategically located in Darmstadt, the facility offers proximity to major clinical trial and biopharmaceutical hubs across Germany, France, Spain, the Netherlands, Belgium and Italy. The location enables companies to streamline drug product release into European markets while navigating increasingly complex development, quality and regulatory landscapes.